DK2186830T3 - Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer deraf - Google Patents
Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer derafInfo
- Publication number
- DK2186830T3 DK2186830T3 DK07800861.2T DK07800861T DK2186830T3 DK 2186830 T3 DK2186830 T3 DK 2186830T3 DK 07800861 T DK07800861 T DK 07800861T DK 2186830 T3 DK2186830 T3 DK 2186830T3
- Authority
- DK
- Denmark
- Prior art keywords
- polyethylene glycol
- applications
- manufacturing process
- interferon alpha
- glycol modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2007/002644 WO2009030066A1 (fr) | 2007-09-04 | 2007-09-04 | Interféron alpha 2b modifié par du polyethylèneglycol et procédé de préparation et applications associés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2186830T3 true DK2186830T3 (da) | 2012-04-02 |
Family
ID=40428422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07800861.2T DK2186830T3 (da) | 2007-09-04 | 2007-09-04 | Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer deraf |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8597635B2 (da) |
| EP (1) | EP2186830B1 (da) |
| JP (1) | JP5325884B2 (da) |
| KR (1) | KR101502645B1 (da) |
| CN (1) | CN101636414B (da) |
| AT (1) | ATE548382T1 (da) |
| AU (1) | AU2007358605B8 (da) |
| BR (1) | BRPI0721984B8 (da) |
| CA (1) | CA2698173C (da) |
| DK (1) | DK2186830T3 (da) |
| ES (1) | ES2382124T3 (da) |
| MX (1) | MX2010002557A (da) |
| PL (1) | PL2186830T3 (da) |
| PT (1) | PT2186830E (da) |
| RU (1) | RU2485134C2 (da) |
| WO (1) | WO2009030066A1 (da) |
| ZA (1) | ZA201001556B (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| CA2698396C (en) * | 2007-09-04 | 2014-01-21 | Biosteed Gene Expression Tech. Co., Ltd. | Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| EP2186830B1 (en) | 2007-09-04 | 2012-03-07 | Biosteed Gene Expression Tech. CO., LTD. | Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof |
| UA109646C2 (uk) * | 2009-12-10 | 2015-09-25 | Терапевтичне застосування кон'югатів білка з полімером | |
| KR101943821B1 (ko) | 2011-06-21 | 2019-01-31 | 한국전자통신연구원 | 무선 통신 시스템에서 제어채널 송수신 방법 |
| RU2622077C2 (ru) * | 2011-09-05 | 2017-06-09 | Ханми Сайенс Ко., Лтд. | Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа |
| EA023323B1 (ru) * | 2013-03-28 | 2016-05-31 | Илья Александрович МАРКОВ | Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона |
| EA022617B1 (ru) * | 2013-03-28 | 2016-02-29 | Илья Александрович МАРКОВ | Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа |
| EA021610B1 (ru) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Жидкое противовирусное лекарственное средство |
| EA037151B1 (ru) * | 2014-11-06 | 2021-02-11 | Фармаэссентия Корпорейшн | Способ лечения с использованием пегилированного интерферона |
| EP3272857B1 (en) * | 2015-03-17 | 2020-08-12 | Shigetaka Shimodaira | Method for preparing dendritic cell by non-adhesive culture using ifn |
| CN106146325B (zh) * | 2015-04-24 | 2019-01-29 | 北京键凯科技股份有限公司 | 一种y型多缩乙二醇衍生物及其制备方法 |
| US20220339248A1 (en) * | 2019-06-19 | 2022-10-27 | The Research Foundation For The State University Of New York | Methods for treating neointimal hyperlasia using f11r/jam-a inhibitors |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| US20230131808A1 (en) * | 2020-04-22 | 2023-04-27 | Southlake Pharmaceuticals, Inc. | Pegylated interferon tau and compositions and methods thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US103411A (en) | 1870-05-24 | Improved liniment | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| CN1243779A (zh) | 1998-07-31 | 2000-02-09 | 东莞中镇鞋材有限公司 | 纤维板及其制造方法 |
| US6610822B2 (en) * | 2000-09-01 | 2003-08-26 | Merck & Co., Inc. | Purification process |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| DE60315145T2 (de) * | 2002-03-13 | 2008-04-30 | Beijing Jiankai Technology Co., Ltd. | Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff |
| WO2004021993A2 (en) * | 2002-09-05 | 2004-03-18 | The General Hospital Corporation | Modified asialo-interferons and uses thereof |
| AU2002356422A1 (en) * | 2002-11-01 | 2004-05-25 | Cadila Healthcare Limited | Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
| RU2005118752A (ru) * | 2002-11-15 | 2006-02-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Позиционные изомеры пэгилированного интерферона l-2а (конъюгата пэг-ifn-l-2а) |
| WO2004076474A2 (en) * | 2003-02-26 | 2004-09-10 | Intermune, Inc. | Polyethylene glycol modified interferon compositions and methods of use thereof |
| KR20080019619A (ko) * | 2005-05-18 | 2008-03-04 | 맥시겐, 인크. | 개량된 인터페론-알파 폴리펩티드 |
| KR20080026135A (ko) * | 2005-06-03 | 2008-03-24 | 암브룩스, 인코포레이티드 | 개선된 인간 인터페론 분자 및 이의 용도 |
| CA2698396C (en) | 2007-09-04 | 2014-01-21 | Biosteed Gene Expression Tech. Co., Ltd. | Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| EP2186830B1 (en) | 2007-09-04 | 2012-03-07 | Biosteed Gene Expression Tech. CO., LTD. | Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof |
-
2007
- 2007-09-04 EP EP07800861A patent/EP2186830B1/en active Active
- 2007-09-04 DK DK07800861.2T patent/DK2186830T3/da active
- 2007-09-04 AT AT07800861T patent/ATE548382T1/de active
- 2007-09-04 PL PL07800861T patent/PL2186830T3/pl unknown
- 2007-09-04 KR KR1020107007270A patent/KR101502645B1/ko active IP Right Grant
- 2007-09-04 AU AU2007358605A patent/AU2007358605B8/en active Active
- 2007-09-04 ES ES07800861T patent/ES2382124T3/es active Active
- 2007-09-04 CN CN2007800505428A patent/CN101636414B/zh active Active
- 2007-09-04 CA CA2698173A patent/CA2698173C/en active Active
- 2007-09-04 US US12/676,525 patent/US8597635B2/en active Active
- 2007-09-04 JP JP2010523253A patent/JP5325884B2/ja active Active
- 2007-09-04 RU RU2010106430/10A patent/RU2485134C2/ru active
- 2007-09-04 MX MX2010002557A patent/MX2010002557A/es active IP Right Grant
- 2007-09-04 WO PCT/CN2007/002644 patent/WO2009030066A1/zh active Application Filing
- 2007-09-04 PT PT07800861T patent/PT2186830E/pt unknown
- 2007-09-04 BR BRPI0721984A patent/BRPI0721984B8/pt active IP Right Grant
-
2010
- 2010-03-03 ZA ZA2010/01556A patent/ZA201001556B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2186830A1 (en) | 2010-05-19 |
| ATE548382T1 (de) | 2012-03-15 |
| US8597635B2 (en) | 2013-12-03 |
| CN101636414B (zh) | 2012-02-15 |
| AU2007358605B2 (en) | 2011-09-08 |
| MX2010002557A (es) | 2011-12-16 |
| CN101636414A (zh) | 2010-01-27 |
| AU2007358605A1 (en) | 2009-03-12 |
| JP2010538022A (ja) | 2010-12-09 |
| RU2010106430A (ru) | 2011-10-10 |
| US20110158943A1 (en) | 2011-06-30 |
| KR20100082774A (ko) | 2010-07-19 |
| WO2009030066A1 (fr) | 2009-03-12 |
| BRPI0721984A2 (pt) | 2014-03-18 |
| PT2186830E (pt) | 2012-06-20 |
| BRPI0721984B8 (pt) | 2021-05-25 |
| JP5325884B2 (ja) | 2013-10-23 |
| CA2698173C (en) | 2015-02-03 |
| EP2186830B1 (en) | 2012-03-07 |
| ZA201001556B (en) | 2010-12-29 |
| CA2698173A1 (en) | 2009-03-12 |
| AU2007358605B8 (en) | 2012-02-02 |
| EP2186830A4 (en) | 2010-10-20 |
| KR101502645B1 (ko) | 2015-03-13 |
| RU2485134C2 (ru) | 2013-06-20 |
| ES2382124T3 (es) | 2012-06-05 |
| PL2186830T3 (pl) | 2012-09-28 |
| BRPI0721984B1 (pt) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2186830T3 (da) | Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer deraf | |
| CY1114356T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| MX2010001650A (es) | Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales. | |
| CY1112848T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| BR112012014677A2 (pt) | inibidores do vírus da hepatite c | |
| BR112013003101A2 (pt) | inibidores do vírus da hepatite c | |
| MY159958A (en) | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors | |
| CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
| BR112013002729A2 (pt) | inibidores de vírus de hepatite c | |
| ATE547103T1 (de) | Hemmer des hepatitis-c-virus | |
| CL2012001176A1 (es) | Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. | |
| PH12015501276A1 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| CY1113259T1 (el) | Ιμιδαζολυλο διφαινυλο ιμιδαζολια ως αναστολεις ιου ηπατιτιδας c | |
| CO6290682A2 (es) | Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c. | |
| CL2008001005A1 (es) | Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv. | |
| CL2008003819A1 (es) | Compuestos derivados del acido 2-cetoamino benzoico sustituido, inhibidores del virus de la hepatitis c; composicion farmaceutica; y su uso en el tratamiento de una infeccion por vhc. | |
| MX2009010564A (es) | Compuestos de 5,6-dihidro-1h-piridin-2-ona. | |
| MX354676B (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv). | |
| BR112014013972A2 (pt) | inibidores de hcv nssa | |
| CL2021002390A1 (es) | Derivados de pirimidona de anillo fusionado para su uso en el tratamiento de la infección por vhb (virus hepatitis b) o de enfermedades inducidas por el vhb. | |
| BR112014015582A2 (pt) | compostos antivirais | |
| SV2005001919A (es) | Compuestos nucleosidos para el tratamiento de infecciones virales | |
| UY31888A (es) | Compuestos de 1,1-dióxido de [1,2,4,]tiadiazina | |
| CY1115326T1 (el) | Φυτικη συνθεση για τη θεραπεια ή την προληψη ιογενων νοσων του αιματος, που προκαλουνται απο τον ιο της ανθρωπινης ανοσοανεπαρκειας (hiv) ή την ηπατιτιδα c | |
| ATE497978T1 (de) | Pharmazeutische zusammensetzungen von antikörpern von viruserkrankungen |